Novel Dual PPAR δ/γ Partial Agonist Induces Hepatic Lipid Accumulation through Direct Binding and Inhibition of AKT1 Phosphorylation, Mediating CD36 Upregulation

Chemical Research in Toxicology, Journal Year: 2024, Volume and Issue: 37(9), P. 1574 - 1587

Published: Sept. 5, 2024

ZLY06 is a dual agonist of peroxisome proliferator-activated receptor (PPAR) δ/γ, showing potential therapeutic effects on metabolic syndrome. However, our research has revealed that exhibits hepatotoxicity in normal C57BL/6J mice, though the precise mechanism remains unclear. This study aims to investigate manifestations and mechanisms ZLY06-induced hepatotoxicity. We administered via oral gavage mice (once daily for six weeks) monitored various indicators preliminarily explore its Additionally, we further specific using PPAR inhibitors (GW9662 GSK0660) Protein kinase B (AKT) activator (SC79). Results showed led increased serum ALP, ALT AST, as well elevated liver index hepatic lipid levels. There was upregulation gene protein expression metabolism-related molecules

Language: Английский

Integrated network pharmacology, transcriptomics and metabolomics to explore the material basis and mechanism of Danggui-Baishao herb pair for treating hepatic fibrosis

Journal of Ethnopharmacology, Journal Year: 2024, Volume and Issue: 337, P. 118834 - 118834

Published: Sept. 18, 2024

Language: Английский

Gardenia jasminoides extract mitigates acetaminophen-induced liver damage in mice

BMC Complementary Medicine and Therapies, Journal Year: 2024, Volume and Issue: 24(1)

Published: Oct. 19, 2024

Language: Английский